91 – 100 of 119
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2005
-
Mark
Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer.
(
- Contribution to journal › Article
-
Mark
Ki67 and p53 immunohistochemistry reduces interobserver variation in assessment of Barrett's oesophagus.
(
- Contribution to journal › Article
-
Mark
Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
(
- Contribution to journal › Article
-
Mark
ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis
(
- Contribution to journal › Article
-
Mark
High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells.
(
- Contribution to journal › Article
-
Mark
ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells.
(
- Contribution to journal › Article
- 2004
-
Mark
Erythropoietin enhances response to treatment in patients with advanced breast cancer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Retinoblastoma protein function and p16(INK4a) expression in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma of the skin and links between p16(INK4a) expression and infiltrative behavior.
(
- Contribution to journal › Article
-
Mark
Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer
(
- Contribution to journal › Article
-
Mark
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.
(
- Contribution to journal › Article